Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 3/20 | 0.47 |
| ▸ | FEN1 | P39748 | 3/20 | 0.47 |
| ▸ | KIF11 | P52732 | 4/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNG | P07510 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15741697 | 0.87 | CYP2C19 (0.50) | ERCC5FEN1KIF11SCN5ASCN9A | |
| SCHEMBL27454693 | 0.83 | SCN5A (0.43) | KIF11SCN5ASCN9APKMCYP2C19 | |
| SCHEMBL6946377 | 0.82 | CYP2C19 (0.41) | CYP2C19HIF1A | |
| SCHEMBL3535049 | 0.81 | CYP2C19 (0.53) | ERCC5FEN1KIF11CYP2C19HIF1A | |
| SCHEMBL6585600 | 0.81 | KMT2A (0.40) | KIF11CYP2C19HIF1AKDM4ERIPK1 | |
| SCHEMBL5643335 | 0.81 | KCNN4 (0.47) | KIF11CYP2C19HIF1ARIPK1 | |
| SCHEMBL3531218 | 0.80 | MIF (0.52) | ERCC5FEN1CYP2C19 | |
| SCHEMBL6585390 | 0.78 | LMNA (0.46) | ERCC5FEN1KIF11CTBP2KDM4E | |
| SCHEMBL10876037 | 0.75 | CYP19A1 (0.42) | KIF11SCN5ASCN9APKMRIPK1 | |
| SCHEMBL25840100 | 0.75 | GRIN2D (0.48) | KIF11SCN5ASCN9APKMVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | claimed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | claimed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | claimed |
| EP-0986545-B1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6548534-B2 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-0986545-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054159-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | ERCC5 2874/4885FEN1 3366/4885KIF11 4072/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | ERCC5 2684/4885FEN1 3799/4885KIF11 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.